Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zandelisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 13/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 18/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.56 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zandelisib SCHEMBL12936730 | 1.00 | PIK3CB (0.56) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| Zandelisib SCHEMBL29366620 | 1.00 | PIK3CB (0.56) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| Zandelisib SCHEMBL30089332 | 1.00 | PIK3CB (0.56) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12802401 | 0.95 | PIK3CB (0.55) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12936790 | 0.94 | PIK3CB (0.58) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12802727 | 0.93 | PIK3CB (0.55) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12802138 | 0.93 | PIK3CB (0.55) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12802650 | 0.92 | PIK3CB (0.64) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12802393 | 0.91 | PIK3CB (0.62) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12802347 | 0.91 | PIK3CB (0.63) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233821-A | Combination therapy of PI3K inhibitors with PD-1 inhibitors | 梅制药公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-117860758-A | Combination therapy | 梅制药公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4132533-A1 | PREPARATION OF A 1,3,5-TRIAZINYL BENZIMIDAZOLE | MEI Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115697345-A | Preparation of 1,3, 5-triazinylbenzimidazoles | 梅制药公司 | 2023-02-03 | — | — | CN | disclosed |